Doctor of Philosophy (Ph.D.)
Pharmaceutics and Drug Design
University of Missouri-Kansas City
2008
Pradeep Karla, Ph.D. is an associate professor in the College of Pharmacy. obtained his Ph.D. in Pharmaceutical Sciences from the University of Missouri-Kansas City and completed the one-year professional leadership training (LEAD) from the Stanford University, Graduate School of Business.
Karla has been serving as a Vice-Chair of the HU Faculty Senate since August 2022. As a Vice-Chair, he serves as a member of the University Faculty Council and the Steering Committee. Since Karla took charge, significant progress has been made. Karla reactivated the Senate committee work by ensuring that all the Senate committees elected the Chairs and initiated the committee work. Karla held the first comprehensive committee meeting with the senate chairs in January 2023 and documented the findings reported by the chairs. Karla organized the second comprehensive committee chairs' meeting in April 2023. The goal of the second meeting was to measure the progress made on the issues reported during the first meeting and document additional findings. A third comprehensive meeting with the Senate committee chairs is being scheduled in June 2023, and the annual report will be shared with the faculty members.
Karla has been working as an Associate Professor in the Department of Pharmaceutical Sciences. He serves on the executive board of the reputed biopharmaceutical angel investor organization, Washington D.C. Archangels, and serves as a consultant provost and professor for the Washington D.C. Archangels Entrepreneur Training Institute. As a Principal Investigator (PI), Dr. Karla, received a highly competitive AACP New Investigator Grant, NIH-funded KL2 Grant, and several other grants as PI and Co-I. Further, Karla's research on teaching method development includes implementing new technologies to promote active learning in the classroom. His classroom teaching involves integrating the tablet touch interface of faculty and student tablet PCs via a Wi-Fi network to create a real-time interactive platform. Karla received the “Teaching with Technology Award” from the Center for Excellence in Teaching, Learning, and Assessment (CETLA) and Excellence in Teaching Initiatives Grant from Howard University. Dr. Karla's work and student feedback assessment data on implementing the teaching technology can be accessed at the following links:
https://cetla.howard.edu/featured_teacher/archive/karla.html
https://drive.google.com/file/d/1RQoUsO-ckQ4HvRQEfgQhN6KQCeZ1q3Cy/view?usp=sharing
Further, Karla received the Distinguished Faculty Award, Professor of the Year Award, Faculty Professionalism Recognition Award, and multiple other awards at HU-COP. The significance of Karla's group’s research involves the discovery of new drug efflux transporters on human ocular tissue and human immune CD4 T-Cells. Dr. Karla's group findings on new HIV drug targets and the novel formulation design for sustained antiviral drug delivery were awarded a U.S. patent (US patent 1,020,552). Karla's research demonstrated for the first time that these transporters play a vital role in decreased bioavailability of drugs employed in chronic disease states such as glaucoma and HIV. Karla's group’s research was cited by the American Association of Colleges of Pharmacy (AACP) as one of the eight promising research contributions that have the potential for a therapeutic cure for glaucoma.
The AACP citation of Karla's research group work (Title: “Glaucoma, Your Time is Running Out”) can be accessed at the google drive link:
https://drive.google.com/file/d/10KFWzslTtJ8x8yDx-rgWCKnnjhQmGh2J/view?usp=sharing
Pharmaceutics and Drug Design
University of Missouri-Kansas City
2008
Pharmacy
Nagarjuna University
2002
Principal Investigator: MDR Efflux Transporters - New Drug Targets for HIV Drug Delivery. Nov 2022 - Oct 2023. Bristol Myers Squibb. $40,000.
The research grant was awarded to evaluate the role of drug efflux transporters on CD4 Cells in HIV drug delivery. Specifically, the grant was awarded to advance the research findings from the awarded patent – “Karla PK, Inventor; Howard University, assignee. Method of increasing the bioavailability of an HIV Drug. US patent 1,020,552.”
Collaborator: Howard University Research Center for Minority Health and Health Disparities (2U54MD007597-31). June 2019 – Mar. 2023. HU RCMI Grant. $17.3 million.
The goal of Dr. Karla’s proposal is to maintain and support the Center for Drug Efflux Transporters and Drug Metabolism at Howard University, College of Pharmacy.
NAG-PEGylated multilamellar liposomes for BBB-GLUT transporter targeting
The primary objective of the research study is to investigate Glucose (GLUT) transporter targeting of the drug (Citalopram-Hbr) for increased permeability across the Blood-Brain Barrier (BBB). The current study reports the development, physicochemical characterization, cytotoxicity analysis and in-vitro BBB permeability assessment of the Citalopram-Hbr liposomal formulations.
Ocular drug delivery is challenging due to the presence of anatomical and physiological barriers. These barriers can affect drug entry into the eye following multiple routes of administration (e.g., topical, systemic, and injectable). Topical administration in the form of eye drops is preferred for treating anterior segment diseases, as it is convenient and provides local delivery of drugs. Major concerns with topical delivery include poor drug absorption and low bioavailability. To improve the bioavailability of topically administered drugs, novel drug delivery systems are being investigated.
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query
Histone deacetylases (HDACs) are part of a vast family of enzymes with crucial roles in numerous biological processes, largely through their repressive influence on transcription, with serious implications in a variety of human diseases. Among different isoforms, human HDAC2 in particular draws attention as a promising target for the treatment of cancer and memory deficits associated with neurodegenerative diseases. Now the challenge is to obtain a compound that is structurally novel and truly selective to HDAC2 because most current HDAC2 inhibitors do not show isoforms selectivity and suffer from metabolic instability. In order to identify novel, and isoform-selective inhibitors for human HDAC2, we designed a shape-based hybrid query from multiple scaffolds of known chemical classes and validated it to be a more effective approach to discover diverse scaffolds than single-molecule query.